Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy…
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared…
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared…
Phase 2 study results to be presented at The Liver Meeting® 2024 of AASLD BJT-778 900 mg dosed every four weeks…
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use…
Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signalsBOSTON…
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of…
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the…
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit…
The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients…